| Literature DB >> 29942389 |
Ya Di1, Qingjie Meng2, Hongwei Yang3, Kun Li4, Liyan Cao1, Ming Shi4, Zhanzhao Fu1, Hao Di5,6.
Abstract
In this study, tanshinone was extracted from Salvia miltiorrhiza. To improve the utilization and the dissolution of the drug, the tanshinone extractions were prepared at a pharmaceutical nanoscale and in the nanometer range of 100-200 nm. Then, the rate of tumor inhibition and the activity of antioxidant system and the thymus/spleen indices were investigated to find the antitumor effect of nanoparticles of tanshinone in cervical carcinoma-bearing mice. Our data suggest that tanshinone inhibits cervical tumor growth and the rates of tumor inhibition of all drug groups were more than 45%. The highest rate was 70.88% in the high dose of nanoscale tanshinone group. The activities of superoxide dismutase were higher in drug groups than in the model control group, and the concentrations of malondialdehyde were significantly lower. These findings suggested that tanshinone enhance the superoxide dismutase activity of the mice and decrease the malondialdehyde content. It may be one of the mechanisms of antitumor effect of tanshinone. The thymus index and spleen index were higher than normal control or model control. These data suggested that tanshinone also enhanced the immune system of mice.Entities:
Keywords: HPLC; TEM; Tanshinone; U14 cervical carcinoma-bearing mice; antitumor
Year: 2016 PMID: 29942389 PMCID: PMC5998259 DOI: 10.1177/1849543516673446
Source DB: PubMed Journal: Nanobiomedicine (Rij) ISSN: 1849-5435
Figure 1.Results of TT extraction and NT preparation. (a) The retention time of tanshinone standards is 10.132 min (CT), 11.206 min (TI), and 18.979 min (TIIA). (b) Three tanshinone peaks at 10.089 min (CT), 11.162 min (TI), and 18.875 min (TIIA). (c) The TEM result (scale length 200 nm). TT: as total tanshinones; NT: nanoscale tanshinone; CT: cryptotanshinone; TI: tanshinoneI; TIIA: tanshinoneIIA.
Effect of tanshinone on tumor growth in vivo.a
| Group | Dose (mg/kg/day) | Animal number | Tumor weight (g) | Inhibition rate (%) | |
|---|---|---|---|---|---|
| Beginning | End | ||||
| Model control | – | 10 | 9 | 3.64 ± 0.52 | |
| CTX | 25 | 8 | 8 | 1.14 ± 0.19*** | 68.77 |
| TT | 50 | 8 | 8 | 2.00 ± 0.03** | 45.11 |
| 100 | 8 | 8 | 1.45 ± 0.28*** | 60.21 | |
| NT | 50 | 8 | 8 | 1.27 ± 0.13*** | 65.03 |
| 100 | 8 | 8 | 1.06 ± 0.12*** | 70.88 | |
TT: total tanshinones; NT: nanoscale tanshinone; CTX: cyclophosphamide.
aResults are expressed as mean ± SD. Significant differences compared with the model control.
**p < 0.01.
***p < 0.001.
Effect of tanshinone on SOD activity and MDA content of U14-bearing mice.a
| Group | Dose (mg/kg/day) | Liver SOD (U/mg prot) | Serum SOD (U/mL) | Liver MDA (nmol/mg prot) | Serum MDA (nmol/mL) |
|---|---|---|---|---|---|
| Model control | – | 59.59 ± 3.26 | 198.63 ± 3.59 | 6.78 ± 0.63 | 88.82 ± 11.73 |
| CTX | 25 | 63.35 ± 1.37 | 262.50 ± 15.74*** | 7.45 ± 2.35 | 93.50 ± 7.24 |
| TT | 50 | 60.28 ± 5.74 | 184.41 ± 39.46 | 8.20 ± 0.27 | 65.53 ± 9.87** |
| 100 | 65.75 ± 6.23 | 195.33 ± 9.07 | 5.49 ± 0.78* | 42.11 ± 4.69*** | |
| NT | 50 | 60.44 ± 3.85 | 201.25 ± 10.58 | 5.78 ± 1.06* | 50.46 ± 3.75*** |
| 100 | 61.57 ± 4.68 | 217.56 ± 15.11* | 4.27 ± 0.35** | 45.33 ± 5.61*** |
TT: total tanshinones; NT: nanoscale tanshinone; CTX: cyclophosphamide; SOD: superoxide dismutase; MDA: malondialdehyde.
aResults are expressed as mean ± SD. Significant differences compared with the model control.
*p < 0.05
**p < 0.01
***p < 0.001.
Effect of tanshinone on spleen indices and thymus indices in U14-bearing mice.a
| Group | Dose (mg/kg/day) | Body weight increased (g) | Thymus index (mg/10 g) | Spleen index (mg/10 g) |
|---|---|---|---|---|
| Normal | – | 6.18 ± 0.53 | 62.15 ± 5.95 | 52.17 ± 2.51 |
| Model control | – | 2.94 ± 0.28 | 66.58 ± 4.48 | 80.27 ± 7.94* |
| CTX | 25 | 1.84 ± 0.30**## | 35.26 ± 2.35***### | 44.80 ± 2.83*### |
| TT | 50 | 3.77 ± 0.52** | 53.09 ± 8.18 | 80.12 ± 5.11*** |
| 100 | 5.22 ± 0.41*## | 48.88 ± 10.34*# | 145.29 ± 6.67***### | |
| NT | 50 | 4.29 ± 0.10*# | 55.84 ± 3.51*## | 133.64 ± 9.41***### |
| 100 | 6.02 ± 0.54### | 60.25 ± 6.75### | 189.31 ± 12.19***### |
TT: total tanshinones; NT: nanoscale tanshinone; CTX: cyclophosphamide
aResults are expressed as mean ± SD. Significant differences compared with the normal control. Significant differences compared with the model control.
*p < 0.05.
**p < 0.01.
***p < 0.001.
# p < 0.05.
## p < 0.01.
### p < 0.001.